VCIM
APLS

Velan Capital Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Velan Capital Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,000
Closed -$2.99M – 23
2023
Q4 		$2.99M Hold
50,000
– – 1.75% 13
2023
Q3 		$1.9M Buy
+50,000
New +$2.2M 1.53% 16

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Velan Capital Investment Management's APLS Position: Q1 2024 in Review

Velan Capital Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 50,000 shares — an estimated $2.99M sold.

Velan Capital Investment Management first reported a position in APLS in Q3 2023 and held it in 2 quarters. The position peaked at $2.99M in Q4 2023. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Velan Capital Investment Management reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Velan Capital Investment Management sold 50,000 Apellis Pharmaceuticals shares in Q1 2024, an estimated $2.99M.
  • Velan Capital Investment Management first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Velan Capital Investment Management's Apellis Pharmaceuticals position peaked at $2.99M in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Velan Capital Investment Management's 13F filing for Q1 2024, filed 14 May 2024.